| 1 |
35508762 | Absorption, metabolism and excretion of opicapone in human healthy volunteers. | 2022 May 4 |
1 |
| 2 |
32648512 | Safinamide in the treatment of Parkinson's disease. | 2020 Aug |
1 |
| 3 |
30681754 | Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. | 2019 Jul |
1 |
| 4 |
27763682 | Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics. | 2017 Mar |
1 |
| 5 |
27138028 | Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects. | 2016 Mar |
4 |
| 6 |
27137718 | Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. | 2015 Nov |
1 |
| 7 |
24271646 | Effect of moderate liver impairment on the pharmacokinetics of opicapone. | 2014 Mar |
4 |
| 8 |
24925090 | Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. | 2014 Sep |
4 |
| 9 |
23248072 | Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. | 2013 Feb |
6 |
| 10 |
23336248 | Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. | 2013 Nov |
5 |
| 11 |
23476919 | An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma. | 2013 Apr 21 |
2 |